{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:55:32Z","timestamp":1773939332694,"version":"3.50.1"},"reference-count":9,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bulcan.2025.11.015","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T12:43:39Z","timestamp":1770381819000},"page":"436-438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Darolutamide en association avec une th\u00e9rapie anti-androg\u00e9nique\u00a0\u2013\u00a0cancers de la prostate m\u00e9tastatiques hormonosensibles (mHSPC)"],"prefix":"10.1016","volume":"113","author":[{"given":"Pierre","family":"Grassi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc-Antoine","family":"Benderra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2025.11.015_bib0050","unstructured":"Lap\u00f4tre-Ledoux B, Remontet L, Uhry Z, Dantony E, Grosclaude P, et al. Incidence des principaux cancers en France m\u00e9tropolitaine en 2023\u00a0et tendances depuis 1990\/main cancers incidence in metropolitan France in 2023\u00a0and trends since 1990. Diponible sur\u00a0: https:\/\/beh.santepubliquefrance.fr\/beh\/2023\/12-13\/2023_12-13_1.html."},{"issue":"10336","key":"10.1016\/j.bulcan.2025.11.015_bib0055","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3\u00a0study with a 2\u00d72\u00a0factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bulcan.2025.11.015_bib0060","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.bulcan.2023.03.019","article-title":"Nouvelles AMM\u00a0: darolutamide\u00a0\u2013\u00a0trith\u00e9rapie dans le cancer de prostate m\u00e9tastatique hormonosensible","volume":"110","author":"Houdou","year":"2023","journal-title":"Bull Cancer (Paris)"},{"issue":"13","key":"10.1016\/j.bulcan.2025.11.015_bib0065","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"issue":"36","key":"10.1016\/j.bulcan.2025.11.015_bib0070","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2025.11.015_bib0075","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.bulcan.2025.11.015_bib0080","doi-asserted-by":"crossref","first-page":"e17082","DOI":"10.1200\/JCO.2024.42.16_suppl.e17082","article-title":"Real-world intensification beyond androgen deprivation therapy (ADT) in metastatic hormone sensitive prostate cancer (mHSPC) in the United States 2017\u20132023: an administrative claims database study","volume":"42","author":"Raval","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.11.015_bib0085","unstructured":"Darolutamide receives EU approval in third indication for patients with advanced prostate cancer [Internet]. [cit\u00e9 3\u00a0oct 2025]. Disponible sur\u00a0: https:\/\/www.orionpharma.com\/newsroom\/all-news\/releases\/press-releases\/2025\/darolutamide-receives-eu-approval-in-third-indication-for-patients-with-advanced-prostate-cancer\/."},{"issue":"14","key":"10.1016\/j.bulcan.2025.11.015_bib0045","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.2217\/fon-2020-1104","article-title":"Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis","volume":"17","author":"Roumigui\u00e9","year":"2021","journal-title":"Future Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126000536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126000536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:36:17Z","timestamp":1773934577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455126000536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0007455126000536"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.11.015","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Darolutamide en association avec une th\u00e9rapie anti-androg\u00e9nique\u00a0\u2013\u00a0cancers de la prostate m\u00e9tastatiques hormonosensibles (mHSPC)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}